� Kamada (TASE: KMDA), a bio-pharmaceutical company engaged in the development, fabrication and marketing of specialty life-saving therapeutics, announced that it has completed a Phase II Study with Aerosolized Alpha-1 Antitrypsin (AAT), delivered via an optimized eFlow platform nebulizer (PARI Pharma GmbH), in cystic fibrosis (CF). Preliminary results indicate that the product has an excellent condom profile; last data should be available by year-end 2008.
David Tsur, Kamada's CEO expressed satisfaction at the advancement of the company's flagship AAT product for the treatment of cystic fibrosis. "This is a major milestone for Kamada. There is significant potential for the aerosolized version of AAT, which is an innovative approach for handling of chronic inflammatory processes that could potentially prevent degeneration of lung routine. We believe that, pending the successful completion of the trials and registration process, this formulation could considerably improve the timber of liveliness and potentially extend the life expectancy of a wide mountain chain of cystic fibrosis patients."
According to Pnina Strauss, Kamada's Clinical Trials and IP Manager, "We are extremely pleased with this major achievement. Aerosolized giving medication of AAT for cystic fibrosis holds great potential for the treatment of these severely diseased patients. We ar eager to pursue the development of this product and demo the benefit for this patient population as well as other respiratory populations."
About the study
The trial run, which was a double blind, placebo controlled study was performed at the renowned Cystic Fibrosis (CF) Medical Center - Hadassah - Hebrew University Medical Center Mount Scopus in Jerusalem, Israel. The trial aimed at validatory the base hit of the product in CF patients and to assess its potential influence on lung inflammation. The results indicate an excellent safety profile of the product. Further trial details are available at hTTP://www.clinicaltrials.gov.
About Aerosolized AAT
Kamada's Aerosolized AAT, which utilizes an optimized eFlow platform nebuliser (PARI Pharma GmbH), has been designated an Orphan Drug for the handling of CF and Alpha-1 Deficiency, in both Europe and the U.S. This designation grants Kamada various benefits such as enquiry fund support, tax incentives, reduced official fees and seven to twelve days of sole distribution rights, if the company's product is first base on the market. Phase II trials in bronchiectasis are presently ongoing.
About the eFlow� Platform Nebulizer
The eFlow platform atomizer, an electronic, portable nebulizer technology political platform, enables extremely efficient aerosolization of liquid medications via a vibrating, perforated tissue layer. Compared to other spray systems, the eFlow political platform nebulizer derriere produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of prison term. Combined with its silent mode of operation, pocket-sized size (it fits in the palm of your hand), light weight, and battery function, the eFlow platform nebulizer helps quash the core of taking daily inhaled treatments.
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonic and nasal bone administration optimized to advance delivery platforms, such as the eFlow Platform Nebulizer.
About Kamada
Kamada is a world biopharmaceutical fellowship (TASE: KMDA) developing, producing and selling a agate line of specialism life-saving biopharmaceuticals using its proprietary chromatographical purification technologies. Licensed and marketed planetary, several of these peculiarity therapeutics are currently undergoing advanced clinical trials.
http://www.kamada.com
More info
Friday, 5 September 2008
Subscribe to:
Posts (Atom)